Fulcrum Therapeutics

Unlocking gene control mechanisms to develop small molecule therapies

FTX-6058 Clin1b (clinical hold Feb 2023) sickle cell disease; 4 undisclosed programs RD/Clin0 blood disorders, neurologic disorders, muscle disorders, cardiomyopathies

Fulcrum therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases. Inspired by patients, Fulcrum drug discovery begins with a deep exploration of disease biology in patient tissue samples. Fulcrum’s proprietary annotated compound library enables them to systematically approach drug discovery in genetically defined diseases. Drug targets are identified that modify gene expression and analyzed computationally using their proprietary database, FulcrumSeek. Fulcrum’s lead program, losmapimod, is being investigated in clinical trials to beat facioscapulohumeral muscular dystrophy.